Anticholinergic drugs and risk of dementia:case-control study

Richardson, Kathryn, Fox, Chris, Maidment, Ian, Steel, Nicholas, Loke, Yoon K, Arthur, Antony, Myint, Phyo K, Grossi, Carlota M, Mattishent, Katharina, Bennett, Kathleen, Campbell, Noll L, Boustani, Malaz, Robinson, Louise, Brayne, Carol, Matthews, Fiona E and Savva, George M (2018). Anticholinergic drugs and risk of dementia:case-control study. BMJ (Clinical research ed.), 361 ,

Abstract

OBJECTIVES: To estimate the association between the duration and level of exposure to different classes of anticholinergic drugs and subsequent incident dementia. DESIGN: Case-control study. SETTING: General practices in the UK contributing to the Clinical Practice Research Datalink. PARTICIPANTS: 40 770 patients aged 65-99 with a diagnosis of dementia between April 2006 and July 2015, and 283 933 controls without dementia. INTERVENTIONS: Daily defined doses of anticholinergic drugs coded using the Anticholinergic Cognitive Burden (ACB) scale, in total and grouped by subclass, prescribed 4-20 years before a diagnosis of dementia. MAIN OUTCOME MEASURES: Odds ratios for incident dementia, adjusted for a range of demographic and health related covariates. RESULTS: 14 453 (35%) cases and 86 403 (30%) controls were prescribed at least one anticholinergic drug with an ACB score of 3 (definite anticholinergic activity) during the exposure period. The adjusted odds ratio for any anticholinergic drug with an ACB score of 3 was 1.11 (95% confidence interval 1.08 to 1.14). Dementia was associated with an increasing average ACB score. When considered by drug class, gastrointestinal drugs with an ACB score of 3 were not distinctively linked to dementia. The risk of dementia increased with greater exposure for antidepressant, urological, and antiparkinson drugs with an ACB score of 3. This result was also observed for exposure 15-20 years before a diagnosis. CONCLUSIONS: A robust association between some classes of anticholinergic drugs and future dementia incidence was observed. This could be caused by a class specific effect, or by drugs being used for very early symptoms of dementia. Future research should examine anticholinergic drug classes as opposed to anticholinergic effects intrinsically or summing scales for anticholinergic exposure. TRIAL REGISTRATION: Registered to the European Union electronic Register of Post-Authorisation Studies EUPAS8705.

Publication DOI: https://doi.org/10.1136/bmj.k1315
Divisions: Life & Health Sciences
Life & Health Sciences > Pharmacy
Life & Health Sciences > Applied Health Research Group
Additional Information: This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Full Text Link:
Related URLs: https://www.bmj ... t/361/bmj.k1315 (Publisher URL)
Published Date: 2018-04-25
Authors: Richardson, Kathryn
Fox, Chris
Maidment, Ian ( 0000-0003-4152-9704)
Steel, Nicholas
Loke, Yoon K
Arthur, Antony
Myint, Phyo K
Grossi, Carlota M
Mattishent, Katharina
Bennett, Kathleen
Campbell, Noll L
Boustani, Malaz
Robinson, Louise
Brayne, Carol
Matthews, Fiona E
Savva, George M

Download

Export / Share Citation


Statistics

Additional statistics for this record